Artizan Biosciences Financing
Artizan Biosciences, Inc., Corporation just filed form D announcing $5.00 million equity financing. This is a new filing. Artizan Biosciences was able to fundraise $3.00 million so far. That is 60.00% of the offering. The total financing amount was $5.00 million. The private financing document was filed on 2016-10-14. The reason for the financing was: unspecified. The fundraising still has about $2.00 million more and is not closed yet. We have to wait more to see if the offering will be fully taken.
Artizan Biosciences is based in Alabama. The company’s business is Biotechnology. The form D was signed by William Wiesler President. The company was incorporated in 2016. The filler’s address is: C/O Hatteras Venture Partners, 280 S. Mangum Street, Suite 350, Durham, Nc, North Carolina, 27701. William Wiesler is the related person in the form and it has address: C/O Hatteras Venture Partners, 280 S. Mangum Street, Suite 350, Durham, Nc, North Carolina, 27701. Link to Artizan Biosciences Filing: 000168746616000001.
Analysis of Artizan Biosciences Offering
On average, startups in the Biotechnology sector, sell 73.77% of the total offering size. Artizan Biosciences sold 60.00% of the offering. The fundraising is still open. The average offering amount for companies in the Biotechnology industry is $3.08 million. The offering was 2.60% smaller than the average of $3.08 million. Of course this should not be taken as negative. Businesses get financed for a variety of reasons and needs. The minimum investment for this financing is set at $0. If you know more about the reasons for the financing, please comment below.
What is Form D? What It Is Used For
Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
Why Fundraising Reporting Is Good For Artizan Biosciences Also
The Form D signed by William Wiesler might help Artizan Biosciences, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.